Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Alkem is the first company in India to introduce semaglutide in single-shot pre-filled syringe format, expanding treatment options for patients and lowering entry barriers with its affordable pricing. The ready-to-use single shot pre-filled syringe format offers enhanced access, and convenience.
The company has received approval from the Drugs Controller General of India (DCGI) to manufacture and market semaglutide pre-filled syringes for the management of Type 2 diabetes mellitus and obesity as an adjunct to diet and exercise.
In March 2026, Alkem had already launched semaglutide in pre-filled disposable and reusable injection pens format in the Indian market. The company has also received regulatory approval for semaglutide vials, which will be launched soon.
Alkem Laboratories reported 25.11% drop in consolidated net profit to Rs 251.11 crore despite 14.62% jump in revenue from operations to Rs 3,603.32 crore in Q4 March 2026 over Q4 March 2025.
Roto Pumps reported a 55.47% decline in consolidated net profit to Rs 5.73 crore in the quarter ended 31 March 2026, compared with Rs 12.87 crore posted in the corresponding quarter last year.
PC Jeweller reported 58.06% jump in standalone net profit to Rs 150.33 crore on 32.66% increase in revenue from operations to Rs 927.34 crore in Q4 FY26 over Q4 FY25.
PG Electroplast reported 55.34% decline in consolidated net profit to Rs 64.86 crore in Q4 FY26 compared with Rs 145.23 crore posted in Q4 FY25. Revenue from operations dropped 10.11% YoY to Rs 1,716.67 crore in Q4 FY26.
Time Technoplast has reported 20.4% rise in consolidated net profit to Rs 131.84 crore on a 14.2% increase in revenue from operations to Rs 1,676.67 crore in Q4 FY26 over Q4 FY25.
Axiscades Technologies has reported 98.6% drop in consolidated net profit to Rs 0.43 crore in Q4 FY26 from Rs 30.76 crore in Q4 FY25. Revenue for the period under review rose by 1.9% year-on-year (YoY) to Rs 273.01 crore during the period under review.
Gulf Oil Lubricants India has reported 3.44% drop in consolidated net profit to Rs 89.59 crore despite a 10.76% increase in revenue from operations to Rs 1,055.26 crore in Q4 FY26 over Q4 FY25.
EBITDA stood at Rs 517.4 crore in Q4 FY26, up 32.2% YoY. EBITDA margin improved to 14.4% in Q4 FY26 as against 12.4% in Q4 FY25.
During the quarter, R&D expenses stood at Rs 229.3 crore, up 44.67% compared with Rs 158.5 crore in Q4 FY25 and accounted for 6.4% of total revenue. India sales were Rs 2,324.5 crore in Q4 FY26, YoY growth of 8.8%. International sales stood at Rs 1,222.3 crore, up 25.4% YoY.
On an annual basis, the company’s consolidated net profit rose 6.3% to Rs 2,301.80 crore in FY26 compared with Rs 2,165.48 crore in FY25. Revenue from operations jumped 13.48% to Rs 14,712.27 crore in FY26 compared with Rs 12,964.52 crore in FY25.
Vikas Gupta, CEO of Alkem, said, “We are pleased to report that Alkem has recorded its highest ever EBIDTA in FY26, reaffirming the strength of our growth strategy, execution and operational rigour. Our top-line growth was broad-based with both domestic branded generics and international business delivering strong growth. An improving business mix, operating leverage and continued cost discipline drove meaningful margin expansion in FY26.
Our financial performance in Q4 was also marked by strong revenue and EBITDA growth as well as a significant increase of 40.7% in our profit before tax and exceptional item. We enter FY27 on a firm foundation and expect healthy growth across businesses supported by increasing contribution from chronic therapies and a differentiated launch pipeline for international markets.”
Meanwhile, the company’s board recommended a final dividend of Rs 10 per equity share of Rs 2 each for financial year ended 31st March, 2026. The company fixed record date as 7th August, 2026 for final dividend. It will be paid on and from 1st September 2026.
Alkem Laboratories is engaged in the pharmaceutical business with global operations. The company is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products.
For the full year,net profit rose 6.30% to Rs 2301.80 crore in the year ended March 2026 as against Rs 2165.48 crore during the previous year ended March 2025. Sales rose 13.48% to Rs 14712.27 crore in the year ended March 2026 as against Rs 12964.52 crore during the previous year ended March 2025.
Meanwhile, the company’s board recommended a final dividend of Rs 10 per equity share of Rs 2 each for financial year ended 31 st March, 2026. The company fixed record date as 7th August, 2026 for final dividend. It will be paid on and from 1st September 2026.
The counter advanced 1.36% to end at Rs 5,452.25 on the BSE. The stock market remained closed today on account of Bakri Id.
Alkem Laboratories announced the appointment of Chanakya Misra into a senior management position in the company effective from 18 May 2026.